Trials / Conditions / Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
5 registered clinical trials studyying Recurrent Platinum-Resistant Primary Peritoneal Carcinoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Ca NCT03113487 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |